High-Intensity Focused Ultrasound for Hepatocellular Carcinoma

Ultrasound-guided high-intensity focused ultrasound treatment for needle-track seeding of hepatocellular carcinoma: preliminary results.

PURPOSE To evaluate therapeutic efficacy of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation for treatment of needle-track seeding of hepatocellular carcinoma (HCC). MATERIALS AND METHODS Nine patients with needle-track seeding of HCC were treated as outpatients using US-guided HIFU ablation. The mean size of the lesion was 1.8 cm (range 1.1 to 2.6 cm), two lesions wer...

High-Intensity Focused Ultrasound –

High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience.

OBJECTIVE This study aims to evaluate the outcome of patients with hepatocellular carcinoma (HCC) treated by high-intensity focused ultrasound (HIFU) in a single tertiary referral center. BACKGROUND HIFU is the latest developed local ablation technique for unresectable HCC. The initial experience on its efficacy is promising, but the survival benefit of patients undergoing HIFU for HCC is poo...

Method, Effectiveness, and Complications of High Intensity Focused Ultrasound (hifu) Ablation on Hepatocellular Carcinoma (hcc) Treatment

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. High intensity focused ultrasound (HIFU) plays an important role in treatment of HCC. HIFU has two methods in tumor treatment, which have thermal and mechanical effects. The absorption of ultrasound energy causes a rise in temperature at the target point of the tumor. Although necrosis occurs, tissue located near the...

Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization.

PURPOSE To evaluate ultrasonographically (US)-guided high-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization (TACE) in the treatment of stage IVA hepatocellular carcinoma (HCC). MATERIALS AND METHODS Institutional review board approval and informed consent were obtained. From November 1998 to May 2000, 50 consecutive patients with stage IVA HCC (TNM c...